Novo Nordisk’s 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry’s hottest opportunity in recent memory. Novo Nordisk (NYSE: NVO) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working through clinical testing….